Antibody/Targeted-Drug Conjugates 2019

6-8 November 2019, Queen’s University Belfast, Belfast, Northern Ireland, UK

  • Increase font size
  • Default font size
  • Decrease font size

Day Two

Final Conference Programme | Thursday 7th November 2019

Session 4:

Moderator: Graham Cotton
(ALMAC, Belfast, Northern Ireland, UK)

‘A conjugate of an antagonistic anti-EGFR antibody with DM1 is potent in killing cancer cells in vitro and in vivo, while sparing keratinocytes’

Victor Goldmacher
(Forbius (Formation Biologics), Inc., USA)

‘Cysteine-To-Lysine Transfer Antibody Conjugation’
Nafsika Forte and Jamie Baker
(Department of Chemistry, University College London, London, UK)

‘Conjugating payloads to native antibodies without the need of any prior antibody engineering in one or two steps’
Philipp Prost1, Philipp Rene Spycher1, Julia Carina Frei2, Jöri Elias Wehrmüller2, Isabella Attinger-Toller1, Dragan Grabulovski1, Ramona Startk1, Torsten Hechler3, Michael Kulke3, Andreas Pahl3, Martin Behe2 and Roger Schibli2,4
(1 Araris Biotech AG, Zurich, Switzerland; 2 Paul Scherrer Institut, Villigen PSI, Switzerland; 3 Heidelberg Pharma Research GmbH, Ladenburg, Germany; 4 ETH Zurich, Zurich, Switzerland)

Moderator Led Discussion

Coffee Break


Moderator: Roger Beerli
(NBE Therapeutics Ltd, Basel, Switzerland)

‘RAGE as therapeutic target for ADC development: The evidence mounts’

Deya Gonzalez and Steve Conlan
(Swansea University Medical School, Swansea University, Swansea, Wales, UK)

‘Outstanding in vivo stability and tumor targeting performance of the Lx® linker-based Her2-targeting ADC LxC-001, as demonstrated by ELISA-based and radiochemical-imaging strategies’

Joey A. Muns*1, Kevin A. Adamzek1, Niels J. Sijbrandi1, Guus A.M.S. van Dongen2 and Bart A. Nijmeijer1
(1 LinXis BV, Amsterdam, The Netherlands; 2 Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands)

‘Antibody Targeted Amanitin Conjugates (ATACs)’

Stephanie Voss and Andreas Pahl
(Heidelberg Pharma AG, Ladenburg, Germany)

Moderator Led Discussion

Lunch Break


Moderator: Deya Gonzalez (University of Swansea, Swansea, Wales, UK)

‘soloMER™ Biologics; Next generation therapeutics for targeted drug conjugate delivery’

Laura Ferguson
(ELASMOGEN, Aberdeen, Scotland, UK)

‘The Pt(II)-based Lx® linker technology as a plug-and-play platform for a modular approach to antibody-drug conjugates (ADCs)’

Eugen Merkul*1, Niels J. Sijbrandi1, Joey A. Muns1, Ibrahim Aydin1, Hendrik-Jan Houthoff1, Guus A.M.S. van Dongen2
(1 LinXis BV, Amsterdam, The Netherlands; 2 Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands)

‘Assessing the economic impact of integrated ADC manufacturing’
Rob Noel
(ADC Biotechnology Ltd, Deeside Industrial Park, Flintshire, UK)

Moderator Led Discussion

Tea Break

Session 7:

‘Development of first-in-class nanobody-drug conjugates for the targeted therapy of NASH/liver fibrosis’
Bart A. Nijmeijer*1, Erik Schooten1, Sebas Pronk1, Paul J.G.M. Steverink1, Paul van Bergen en Henegouwen2 and Hendrik-Jan Houthoff1
(1 LinXis BV, Amsterdam, The Netherlands; 2 Department of Cell Biology, Utrecht University, Utrecht, The Netherlands)

‘Rational library design for antibody affinity maturation: Exploring case study data’
Anthony O’Kane
(Fusion Antibodies, Belfast, Northern Ireland, UK)

‘Title to be confirmed’
Ryan Donnelly
(QUB Belfast, Northern Ireland, UK)

Moderator Led Discussion


ATDC 2019 Delegates

Login details will be supplied after you have registered for the event.

ATDC 2019 Sponsors

  • NBE Therapeutics
  • ImmunoGen
  • ADC Review
  • OncoZine
  • Genentech
  • Genovis
  • Almac Discovery
  • LinXis
  • Lonza
  • Aldevron
  • Cancer Targeting Solutions Consulting
  • Catalent Biologics
  • Sutro Biopharma

ATDC 2019 Downloads

ATDC 2019 Leaflet

ATDC 2019 Mailing List

E-mail Address
What is 3+2-1?